We investigatedthe in vivo and in vitro effectsof aspirinon several clinicalassays of glycosylatedhemoglobin.Acetylation of hemoglobinfalsely increasedthe glycosylatedhemoglobinfractionmeasured by "high-performance"liquidchro- ) is cited as a drug that interferes with the determination of glycosylated hemoglobin (4), although no published studies have evaluated its effect on the commonly used clinical assays. Aspirin has many similarities to glucose; it has the same molecular mass, causes posttranslational modification of lysine residues, and confers a negative charge on the modified protein (5). We investigated the acetylation of hemoglobin by aspirinin vitro and in vivo and studied the resulting interference with glycosylated hemoglobin assays.
(8), and a colorimetric assay (9) according to previously published methods with the following modifications.
To isolate and purify the hemoglobin A0 and hemoglobin A1 fractions that were used in the in vitro incubations, we used HPLC with a 16 cm x 9 mm (i.d.) column. The isolated hemoglobin A0 and hemoglobin A1 fractions were at least 99% pure.
Diabetes Unit and Medical Services, MassachusettsGeneral Hospital, and the Department of Medicine, Harvard Medical School, Boston,MA 02114.
Address correspondence to D.M.N. at the Diabetes Unit, Massachusetts General Hospital.
ReceivedJuly 28, 1982; accepted Oct. 12, 1982.
For isoelectric focusing, we used 0.4 x 10 cm rod gels, NaOH (20 mmol/L) catholyte, and phosphoric acid (10 mmol/L) anolyte. We applied approximately 300 zg of protein in a 25-L volume to the gel. The current was 1 mA per tube and the voltage was maintained at 500 V. The assay was performed at 4#{176}C.
Unlike the other methods, the colorimetric assay is specific for glycosylated and not acetylated hemoglobin (9). We adjusted the concentration of hemoglobin in the assay to 20 g/L to provide reproducible colorimetric results and included a fructose standard with each run. After incubation of hemolysate with oxalic acid, 0.5 molJL, in an autoclave (124 #{176}C, 124 kPa) for 1 h, we cooled the solution in ice, precipitated protein with trichloroacetic acid (400 g/L) and ifitered the solution through a 0.45-sm (pore size) syringe filter. The interassay coefficient of variation based on eight repeated assays was <5% for samples from non-diabetics and <4% for samples from diabetics.
HemoglobinAcetylation
Whole blood was collected into EDTA-containing tubes.
Erythrocytes were washed twice in isotonic saline and then incubated in 10 volumes of isotonic saline for 14 hat 22 #{176}C to remove the labile glycosylated fraction before hemolysis (6).
Acetylated
hemoglobin was generated in vitro by incubating either erythrocytes,hemolysate, or purified hemoglobin A0 or A1 (1 g/L) with acetylsalicylic acid, 0.1 to 14 mmolJL, at 38#{176}C for 0.5 to 24 h. Besides the hemoglobin and acetylsalicylic acid, the incubation medium contained phosphate buffer (10 mmolfL, pH 6.9) prepared from NaH2PO4 and Na2HPO4. A control incubation, without acetylsalicylic acid, was performed under otherwise identical conditions. The [3Hlacetylsalicylic acid was purified by HPLC chromatography in the above solvent at a flow rate of 1 mL/min on a C18 analyticalcolumn (Altex Scientific Inc., Berkeley, CA 94710) (10). The acetylsalicylic peak, monitored at 275 nm with a flow-through spectrophotometer (Model 100-40; Hitachi Instruments, Tokyo, Japan), was collected, evaporated under reduced pressure, and stored at -80 #{176}C. No hydrolysis of this sample was detected by HPLC after storage for two months.
To 
Studies on Patients
A normal, nondiabetic volunteer ingested 600 mg of aspirin daily for three weeks and 2.4 g daily for four weeks. We assayed hemoglobin A1 by HPLC at two-week intervals during this period. We also studied 23 subjects with rheumatoid arthritis, no history of diabetes, and normal values for plasma glucose during fasting, who had ingested least 4 g of aspirin daily for three months. EDTA-anticoagulated blood samples were obtained and assayed for glycosylated hemoglobin by the HPLC and colorimetric method, and for plasma salicylate concentration (11).
Results
The addition of acetylsalicylic acid (final concentration 4.6 mmol/L) directly to the hemolysate prepared for HPLC or electrophoretic assay did not alter the results (data not shown). Incubation of washed erythrocytes, hemolysate, or hemoglobin A0 with various concentrations of acetylsalicylic acid, however, produced an apparent increase in the glycosylated fraction as measured with HPLC or electrophoresis, an increase that was time-and concentration-dependent (Figure 1) . The qualitative profile of the acetylated product was When purified hemoglobin A1 was incubated with acetylsalicylic acid, there was a gradual increase in a peak that comigrated with the minor glycosylated fractions hemoglobin Aia and Aib on HPLC. Incubation of the acetylated hemoglobin in isotonic saline (38 #{176}C, 5 h) did not alter the size of the new minor fractions. With isoelectric focusing, the acetylated product migrated cathodically from the glycosylated product and was clearly separable (data not shown).
Incubation of hemoglobin A0 with E3Hlacetylsalicylic acid
revealed that incorporation of the l3Hlacetyl group was predominantly confined to the fractions represented by the minor peaks. There was 10-fold greater incorporation (moles of acetylsalicylic acid per mole of hemoglobin) into these minor fractions than into the hemoglobin A0 fraction (Figure 3) . The calculated incorporation of tritiated acetate into the fast-migrating peaks was approximately 2 mol per mole of quatrameric hemoglobin. There was a slight but appreciable increase of glycosylated hemoglobin, from 4.7 to 5.0% and 5.0 to 5.4%, during the period when the normal volunteer and 91% had values exceeding 1 SD above the non-diabetic means with the HPLC assay (mean 4.98, SD 0.67). There was no correlation between plasma salicylic acid concentration and the size of the fast peaks. The colorimetric assay, which measures only the glycosylated fraction, showed values for all of the subjects except one that were within the normal range (Figure 4) .
Discussion
The measurement of glycosylated hemoglobin has assumed an increasingly important role in the management of diabetes. The vagaries of the clinical assays have been defined and refined. On theoreticgrounds, the acetylation of hemoglobin by aspirin would be expected to interfere with clinical assays that separate glycosylated hemoglobin on the (17) .
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